Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia

Bone Marrow Transplantation

Volumn 36, Issue 2, 2005, Pages 157-162

  Hosing, C ^a   Saliba, R M ^a   Shahjahan, M ^a   Estey, E H ^a   Couriel, D ^a   Giralt, S ^a   Andersson, B ^a   Champlin, R E ^a   De Lima, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myelogenous leukemia; Allogeneic transplantation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUSULFAN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MELPHALAN; METHOTREXATE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TUMOR BURDEN;

EID: 22744439393     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705011     Document Type: Article

References (27)

1. Frassoni F, Barrett A, Granena A et al. Relapse after allogeneic bone marrow transplantation for acute leukemia: a survey by the EBMT of 117 cases. Br J Haematol 1988; 70: 317-320.
2. Collins R, Shpilberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
3. Bacigalupo A, Soracco M, Vassallo F et al. Donor lymphocyte infusion (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 927-932.
4. Kolb H, Schattenberg A, Goldman J et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
5. Radich JP, Gooley T, Sanders JE et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272-279.
6. Bosi A, Laszlo D, Labopin M, et al, for the Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675-3684.
7. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
8. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80-83.
9. Stata Corporation. StataCorp: Stata Statistical Software: Release 7.0. Stata Corporation: College Station, TX, 2001.
10. Champlin R, Khouri I, Shimoni A et al. Harnessing graft versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
11. Andersson BS, Kashyap A, Gian V et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145-154.
12. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
13. Ravandi F, Kantarjian H, Cohen A et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 2001; 27: 1221-1225.
14. de Lima M, van Besien K, Gajewski J et al. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant 2000; 26: 333-338.
15. de Lima M, Couriel D, Thall PF et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
16. Bibawi S, Abi-Said D, Fayad L et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 2001; 67: 227-233.
17. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
18. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogencic progenitor cell transplantation. Blood 2001; 97: 631-637.
19. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
20. Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461-466.
21. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269-275.
22. Eapen M, Giralt SA, Horowitz MM et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721-727.
23. Michallet M, Tanguy ML, Socie G et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol 2000; 108: 400-407.
24. Russell J, Bowen T, Brown C et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hematopoietic cells. Bone Marrow Transplant 1996; 18: 501-505.
25. Al-Qurashi F, Ayas M, Al Sharif F et al. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution. Hematology 2004; 9: 123-129.
26. Wong R, Shahjahan M, Wang X et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transpl 2005; 11: 108-114.
27. Grandage VL, Cornish JM, Pamphilon DH et al. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation. Bone Marrow Transplant 1998; 21: 687-690.